U.S. Markets close in 1 hr 20 mins

COVID-19 Impacts: Non-Tumorous Skin Diseases Therapeutics Market will Accelerate at a CAGR of over 9% through 2020-2024 | Misdiagnosis of Skin Diseases to Boost Growth | Technavio

Technavio has been monitoring the non-tumorous skin diseases therapeutics market and it is poised to grow by USD 12.93 billion during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200724005304/en/

Technavio has announced its latest market research report titled Global Non-Tumorous Skin Diseases Therapeutics Market 2020-2024 (Graphic: Business Wire)

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request the Latest Free Sample Report on COVID-19 Impact

Frequently Asked Questions-

  • What is the year-over-year growth of the non-tumorous skin diseases therapeutics market in 2020?
    Technavio says that the year-over-year growth of the market is 7.19% in 2020.
  • At what rate is the market projected to grow during the forecast period 2020-2024?
    Growing at a CAGR of over 9%, the market growth will accelerate in the forecast period.
  • What is the key factor driving the market?
    Misdiagnosis of skin diseases.
  • Who are the top players in the market?
    AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Eli Lilly and Co., Galderma Laboratories LP, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd. are the top players in the market.
  • Which region is expected to hold the highest market share?
    North America.
  • What is the major trend for the non-tumorous skin diseases therapeutics market?
    Increasing healthcare expenditure.
  • Based on segmentation by application, which segment is expected to witness the fastest growth in the global market?
    Psoriasis.

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Eli Lilly and Co., Galderma Laboratories LP, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Misdiagnosis of skin diseases has been instrumental in driving the growth of the market. However, the increasing availability of generic therapeutics might hamper market growth.

Non-Tumorous Skin Diseases Therapeutics Market 2020-2024: Segmentation

Non-Tumorous Skin Diseases Therapeutics Market is segmented as below:

  • Application
    • Psoriasis
    • Eczema
    • Acne Vulgaris
    • Other Applications
  • Geographic Landscape
    • Asia
    • Europe
    • North America
    • ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40772

Non-Tumorous Skin Diseases Therapeutics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our non-tumorous skin diseases therapeutics market report covers the following areas:

  • Non-Tumorous Skin Diseases Therapeutics Market size
  • Non-Tumorous Skin Diseases Therapeutics Market trends
  • Non-Tumorous Skin Diseases Therapeutics Market industry analysis

This study identifies increasing healthcare expenditure as one of the prime reasons driving the non-tumorous skin diseases therapeutics market growth during the next few years.

Non-Tumorous Skin Diseases Therapeutics Market 2020-2024: Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the non-tumorous skin diseases therapeutics market, including some of the vendors such as AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Eli Lilly and Co., Galderma Laboratories LP, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd. Backed with competitive intelligence and benchmarking, our research reports on the non-tumorous skin diseases Therapeutics Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Non-Tumorous Skin Diseases Therapeutics Market 2020-2024: Key Highlights

  • CAGR of the market during the forecast period 2020-2024
  • Detailed information on factors that will assist non-tumorous skin diseases therapeutics market growth during the next five years
  • Estimation of the non-tumorous skin diseases therapeutics market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the non-tumorous skin diseases therapeutics market
  • Analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of non-tumorous skin diseases therapeutics market vendors

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Psoriasis - Market size and forecast 2019-2024
  • Eczema - Market size and forecast 2019-2024
  • Acne vulgaris - Market size and forecast 2019-2024
  • Other applications - Market size and forecast 2019-2024
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Business strategies
  • Misdiagnosis of skin diseases
  • Increasing healthcare expenditure

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Amgen Inc.
  • Bausch Health Companies, Inc.
  • Eli Lilly and Co.
  • Galderma Laboratories LP
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200724005304/en/

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/